A hub for independent voices and hard truths
Feb 10 (Reuters) – The U.S. Food and Drug Administration will not review Moderna’s (MRNA) approval application for its influenza vaccine, the company said on Tuesday, sending its shares down 8% in extended trading. In its refusal-to-file letter, the FDA …
Today we provided an update on regulatory submissions for our investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 years and older. Moderna has filed for marketing authorization with the U.S. Food and Drug Administration, the European Medicines Agency, Health… …
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products …
In a significant development in the pharmaceutical industry, Merck and Moderna have announced a partnership focused on advancing mRNA technology specifically for cancer therapeutics. This collaboration marks a pivotal step towards exploring the potential of mRNA technology beyond its application …
Moderna plans to cut about 10% of its global workforce by the end of 2025. The move reflects declining Covid vaccine sales and efforts to reduce operating costs by approximately $1.5 billion through 2027. “Given the evolving market dynamics, we …
GOOD NEWS EVERBODY –Let's keep it going down pic.twitter.com/U8eK91emsl — Paul Cooper (@XxWxX888) April 12, 2025
Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio. Moderna now expects 2025 revenue to come …
